Methods for Promoting Myelination, Neuronal Survival and Oligodendrocyte Differentiation Via Administration of SP35 or TrkA Antagonists
AssigneeBiogen Idec MA Inc.
InventorsSha Mi, Vincent Jung
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for promoting myelination, neuronal survival, and oligodendrocyte differentiation and treating demyelination and dysmyelination disease by the administration of a TrkA antagonist. The invention also relates to methods of inhibiting or decreasing Sp35 expression by the use of a TrkA antagonist. Additionally, the invention relates generally to methods for blocking Sp35 and TrkA interaction and inhibiting or decreasing TrkA phosphorylation by the administration of a Sp35 antagonist.
Claims57
A method for promoting myelination of central nervous system (CNS) neurons, comprising contacting a mixture of CNS neurons and oligodendrocytes with a composition comprising a TrkA antagonist selected from the group consisting of:
- (i) a TrkA antagonist compound;
- (ii) a TrkA antagonist polypeptide;
- (iii) a TrkA antagonist antibody or fragment thereof;
- (iv) a TrkA antagonist polynucleotide;
- (v) a TrkA aptamer;
- and
- (vi) a combination of two or more of said TrkA antagonists.
2-3. (canceled)
A method for promoting survival of CNS neurons in a mammal, comprising administering to a mammal in need thereof an effective amount of a composition comprising a TrkA antagonist selected from the group consisting of:
- (i) a TrkA antagonist compound;
- (ii) a TrkA antagonist polypeptide;
- (iii) a TrkA antagonist antibody or fragment thereof;
- (iv) a TrkA antagonist polynucleotide;
- (v) a TrkA aptamer;
- and
- (vi) a combination of two or more of said TrkA antagonists.
A method for inhibiting Sp35 expression in CNS neurons comprising contacting CNS neurons with a composition comprising a TrkA antagonist selected from the group consisting of:
- (i) a TrkA antagonist compound;
- (ii) a TrkA antagonist polypeptide;
- (iii) a TrkA antagonist antibody or fragment thereof;
- (iv) a TrkA antagonist polynucleotide;
- (v) a TrkA aptamer;
- and
- (vi) a combination of two or more of said TrkA antagonists.
(canceled)
8-9. (canceled)
(canceled)
15-16. (canceled)
(canceled)
20-23. (canceled)
(canceled)
27-31. (canceled)
35-39. (canceled)
(canceled)
44-47. (canceled)
49-55. (canceled)
A method for inhibiting TrkA phosphorylation comprising contacting CNS neurons with a composition comprising a Sp35 antagonist selected from the group consisting of:
- (i) a soluble Sp35 polypeptide;
- (ii) an Sp35 antibody or fragment thereof;
- (iii) an Sp35 antagonist polynucleotide;
- (iv) an Sp35 aptamer;
- and
- (iv) a combination of two or more of said Sp35 antagonists.
57-59. (canceled)
61-62. (canceled)
(canceled)
70-71. (canceled)
(canceled)
75-78. (canceled)
(canceled)
83-86. (canceled)
(canceled)
90-98. (canceled)
Dependencies are inferred from the claim text.